Sequence-Specific Targeting of Bacterial Resistance Genes Increases Antibiotic Efficacy

PLoS Biology

Volumn 14, Issue 9, 2016, Pages

  Ayhan, Dilay Hazal ^a,b   Tamer, Yusuf Talha ^a   Akbar, Mohammed ^a   Bailey, Stacey M ^c   Wong, Michael ^c,d   Daly, Seth M ^e   Greenberg, David E ^e   Toprak, Erdal ^a,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c AVI BIOPHARMA INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CARBENICILLIN; CEFOTAXIME; CEFOXITIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; NITROFURANTOIN; OLIGOMER; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SPECTINOMYCIN; SPIRAMYCIN; SULFAMONOMETHOXINE; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; ACRAB-TOLC PROTEIN, E COLI; ANTIINFECTIVE AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CARRIER PROTEIN; ESCHERICHIA COLI PROTEIN; PENICILLANIC ACID; PIPERACILLIN; SULFAMETHOXAZOLE; TAZOBACTAM;

ACRA GENE; ACRB GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; NONHUMAN; TOLC GENE; ANALOGS AND DERIVATIVES; CELL LINE; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; NUCLEOTIDE SEQUENCE; PROCEDURES;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; CARRIER PROTEINS; CELL LINE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI PROTEINS; GENE KNOCKDOWN TECHNIQUES; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PENICILLANIC ACID; PIPERACILLIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

EID: 84992109011     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002552     Document Type: Article

References (47)

1. Levy SB, Marshall B, Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10: S122–129. 15577930
2. Szybalski W, Bryson V, Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol. 1952;64: 489–499. 12999676
3. Alekshun MN, Levy SB, Molecular mechanisms of antibacterial multidrug resistance. Cell. 2007;128: 1037–1050. 17382878
4. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011;9: 894–896. doi: 10.1038/nrmicro269322048738
5. Oz T, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, et al. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol. 2014;31: 2387–2401. doi: 10.1093/molbev/msu19124962091
6. Imamovic L, Sommer MO, Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 2013;5: 204ra132. doi: 10.1126/scitranslmed.300660924068739
7. Lazar V, Pal Singh G, Spohn R, Nagy I, Horvath B, Hrtyan M, et al. Bacterial evolution of antibiotic hypersensitivity. Mol Syst Biol. 2013;9: 700. doi: 10.1038/msb.2013.5724169403
8. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA, Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 2013;41: 7429–7437. doi: 10.1093/nar/gkt52023761437
9. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32: 1146–1150. doi: 10.1038/nbt.304325282355
10. Citorik RJ, Mimee M, Lu TK, Bacteriophage-based synthetic biology for the study of infectious diseases. Curr Opin Microbiol. 2014;19: 59–69. doi: 10.1016/j.mib.2014.05.02224997401
11. Greenberg DE, Marshall-Batty KR, Brinster LR, Zarember KA, Shaw PA, Mellbye BL, et al. Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis. 2010;201: 1822–1830. doi: 10.1086/65280720438352
12. Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM, Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug Chem. 2007;18: 50–60. 17226957
13. Deere J, Iversen P, Geller BL, Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother. 2005;49: 249–255. 15616302
14. Geller BL, Deere JD, Stein DA, Kroeker AD, Moulton HM, Iversen PL, Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother. 2003;47: 3233–3239. 14506035
15. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD, Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 1996;6: 267–272. 9012862
16. Geller BL, Deere J, Tilley L, Iversen PL, Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. J Antimicrob Chemother. 2005;55: 983–988. 15872045
17. Nichols RJ, Sen S, Choo YJ, Beltrao P, Zietek M, Chaba R, et al. Phenotypic landscape of a bacterial cell. Cell. 2011;144: 143–156. doi: 10.1016/j.cell.2010.11.05221185072
18. Liu A, Tran L, Becket E, Lee K, Chinn L, Park E, et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob Agents Chemother. 2010;54: 1393–1403. doi: 10.1128/AAC.00906-0920065048
19. Tamae C, Liu A, Kim K, Sitz D, Hong J, Becket E, et al. Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J Bacteriol. 2008;190: 5981–5988. doi: 10.1128/JB.01982-0718621901
20. Blair JM, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekathfer U, et al. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. Proc Natl Acad Sci U S A. 2015;112: 3511–3516. doi: 10.1073/pnas.141993911225737552
21. Webber MA, Piddock LJ, The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother. 2003;51: 9–11. 12493781
22. Piddock LJ, Multidrug-resistance efflux pumps—not just for resistance. Nat Rev Microbiol. 2006;4: 629–636. 16845433
23. Nilsen IW, Bakke I, Vader A, Olsvik O, El-Gewely MR, Isolation of cmr, a novel Escherichia coli chloramphenicol resistance gene encoding a putative efflux pump. J Bacteriol. 1996;178: 3188–3193. 8655497
24. Tate CG, Kunji ERS, Lebendiker M, Schuldiner S, The projection structure of EmrE, a proton-linked multidrug transporter from Escherichia coli, at 7 A resolution. EMBO J. 2001;20: 77–81. 11226157
25. Blair JM, Smith HE, Ricci V, Lawler AJ, Thompson LJ, Piddock LJ, Expression of homologous RND efflux pump genes is dependent upon AcrB expression: implications for efflux and virulence inhibitor design. J Antimicrob Chemother. 2015;70: 424–431. doi: 10.1093/jac/dku38025288678
26. Blair JM, Richmond GE, Piddock LJ, Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol. 2014;9: 1165–1177. doi: 10.2217/fmb.14.6625405886
27. Marshall NJ, Piddock LJ, Antibacterial efflux systems. Microbiologia. 1997;13: 285–300. 9353747
28. Coldham NG, Webber M, Woodward MJ, Piddock LJ, A 96-well plate fluorescence assay for assessment of cellular permeability and active efflux in Salmonella enterica serovar Typhimurium and Escherichia coli. J Antimicrob Chemother. 2010;65: 1655–1663. doi: 10.1093/jac/dkq16920513705
29. Munck C, Gumpert HK, Wallin AI, Wang HH, Sommer MO, Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci Transl Med. 2014;6: 262ra156. doi: 10.1126/scitranslmed.300994025391482
30. Yeh P, Tschumi AI, Kishony R, Functional classification of drugs by properties of their pairwise interactions. Nat Genet. 2006;38: 489–494. 16550172
31. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011;7: 544. doi: 10.1038/msb.2011.7122068327
32. Michel JB, Yeh PJ, Chait R, Moellering RC, Jr.Kishony R, Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A. 2008.
33. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R, Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A. 2008;105: 13977–13981. doi: 10.1073/pnas.080596510518779569
34. Chait R, Craney A, Kishony R, Antibiotic interactions that select against resistance. Nature. 2007;446: 668–671. 17410176
35. Tegos GP, Haynes M, Strouse JJ, Khan MM, Bologa CG, Oprea TI, et al. Microbial efflux pump inhibition: tactics and strategies. Curr Pharm Des. 2011;17: 1291–1302. 21470111
36. Sun J, Deng Z, Yan A, Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun. 2014;453: 254–267. doi: 10.1016/j.bbrc.2014.05.09024878531
37. Stavri M, Piddock LJ, Gibbons S, Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother. 2007;59: 1247–1260. 17145734
38. Garvey MI, Piddock LJ, The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB. Antimicrob Agents Chemother. 2008;52: 1677–1685. doi: 10.1128/AAC.01644-0718362193
39. Baugh S, Phillips CR, Ekanayaka AS, Piddock LJ, Webber MA, Inhibition of multidrug efflux as a strategy to prevent biofilm formation. J Antimicrob Chemother. 2014;69: 673–681. doi: 10.1093/jac/dkt42024176982
40. Zhao X, Drlica K, Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33Suppl 3: S147–156. 11524712
41. Tilley LD, Mellbye BL, Puckett SE, Iversen PL, Geller BL, Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. J Antimicrob Chemother. 2007;59: 66–73. 17079242
42. Puckett SE, Reese KA, Mitev GM, Mullen V, Johnson RC, Pomraning KR, et al. Bacterial resistance to antisense peptide phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother. 2012;56: 6147–6153. doi: 10.1128/AAC.00850-1222985881
43. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006;2: 20060008. 16738554
44. Thomason LC, Costantino N, Court DL, E. coli genome manipulation by P1 transduction. Curr Protoc Mol Biol. 2007;Chapter 1: Unit 1 17.
45. Datsenko KA, Wanner BL, One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000;97: 6640–6645. 10829079
46. Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release. 2006;116: 304–313. 17097177
47. Palmer AC, Toprak E, Baym M, Kim S, Veres A, Bershtein S, et al. Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes. Nat Commun. 2015;6: 7385. doi: 10.1038/ncomms838526060115